

CITATION REPORT

List of articles citing

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study

DOI: PM/23396737

Annals of Hepatology, 2013, 12, 256-62.

Source: <https://exaly.com/paper-pdf/133653457/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
102	More on current evidences on probiotics as a novel treatment for non-alcoholic Fatty liver disease. 2013 , 13, e13780		1
101	Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. 2013 , 19, 6911-8		227
100	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. 2013 , 8, e62885		205
99	Is there a role for probiotics in liver disease?. 2014 , 2014, 874768		15
98	The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. 2014 , 6, 5583-99		65
97	Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. 2014 , 20, 15518-31		111
96	Non-alcoholic fatty liver disease: what the clinician needs to know. 2014 , 20, 12956-80		117
95	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. 2014 , 15, 684-711		21
94	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. 2014 , 39, 1276-85		269
93	NASH and the Cross-Talk Between the Gut and Liver. 2014 , 2, 211-217		1
92	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. 2014 , 20, 16841-57		31
91	Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. 2015 , 1, 356-367		48
90	Gut microbiota and liver diseases. 2015 , 21, 1691-702		94
89	Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. 2015 , 7, 559-65		29
88	Treatment of nonalcoholic steatohepatitis in adults: present and future. 2015 , 2015, 732870		19
87	Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. 2015 , 48, 923-30		165
86	Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. 2016 , 17, 300		49

85	Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. 2016 , 17, 481	70
84	Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. 2016 , 17,	160
83	Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. 2016 , 8,	60
82	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. 2016 , 311, G1018-G1036	49
81	A Bugs Battle on Behalf of the Liver. 2016 , 23, 126-129	
80	Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1365-74	72
79	Probiotic supplementation in children with cystic fibrosis-a systematic review. 2016 , 175, 1255-66	28
78	Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. 2016 , 6, 32002	156
77	The role of the gut microbiota in NAFLD. 2016 , 13, 412-25	459
76	Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. 2016 , 9, 463-72	28
75	Targeting Dysbiosis for the Treatment of Liver Disease. 2016 , 36, 37-47	30
74	Probiotics in prevention and treatment of obesity: a critical view. 2016 , 13, 14	171
73	Gut Microbiota of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1268-81	37
72	Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?. 2016 , 150, 1745-1755.e3	86
71	Probiotics for people with hepatic encephalopathy. 2017 , 2, CD008716	48
70	Fecal microbiota transplantation in metabolic syndrome: History, present and future. 2017 , 8, 253-267	144
69	Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. 2017 , 3, 101-113	39
68	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. 2017 , 8, 240-252	85

67	Non-alcoholic Fatty Liver Disease in Non-obese Patients. 2017 , 16, 382-390	
66	Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. 2017 , 7, 130-137	33
65	Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. 2017 , 9,	100
64	Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. 2017 , 9,	54
63	Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. 2017 , 9,	793
62	Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. 2017 , 4,	59
61	Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats. 2017 , 17, 455	15
60	Gut bacteria may control development of hepatocellular carcinoma. 2017 , 6, 417-419	5
59	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. 2018 , 2, 43-51	44
58	Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. 2018 , 57, 2037-2053	23
57	Is It Time to Use Probiotics to Prevent or Treat Obesity?. 2018 , 10,	55
56	Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. 2018 , 9, 1813	44
55	Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. 2018 , 24, 331-338	15
54	Gut?Liver Axis: How Do Gut Bacteria Influence the Liver?. 2018 , 6,	53
53	The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. 2018 , 14, 701-706	17
52	Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. 2019 , 58, 1735-1745	44
51	Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. 2019 , 20, 580	5
50	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. 2019 , 11,	42

49	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2019 , 12, 1756284819878046	20
48	Effect of N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. 2019 , 15, 1336-1344	21
47	The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). 2019 , 76, 1541-1558	161
46	ESPEN guideline on clinical nutrition in liver disease. 2019 , 38, 485-521	202
45	Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. 2019 , 110, 139-149	50
44	Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2019 , 64, 3402-3412	33
43	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. 2019 , 50, 144-158	26
42	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. 2019 , 11,	71
41	Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. 2019 , 103, 668-678	12
40	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. 2019 , 7,	24
39	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. 2019 , 244, 408-418	9
38	Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. 2019 , 9, 5688	59
37	Histopathological Features and Composition of Gut Microbiota in Rhesus Monkey of Alcoholic Liver Disease. 2019 , 10, 165	10
36	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. 2019 , 11,	23
35	Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. 2019 , 2019, 1484598	19
34	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. 2020 , 55, 142-158	41
33	Gestational Diabetes Is Uniquely Associated With Altered Early Seeding of the Infant Gut Microbiota. 2020 , 11, 603021	9
32	Efficacy of Dietary Supplements to Reduce Liver Fat. 2020 , 12,	5

31	Microbial Metabolites: Critical Regulators in NAFLD. 2020 , 11, 567654	12
30	Recipe for a Healthy Gut: Intake of Unpasteurised Milk Is Associated with Increased Abundance in the Human Gut Microbiome. 2020 , 12,	19
29	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. 2020 , 35, 261-274	14
28	Effects of therapeutic probiotics on modulation of microRNAs. 2021 , 19, 4	12
27	THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW. 2021 , 39, e2019226	2
26	Therapeutic approaches for non-alcoholic steatohepatitis. 2021 , 12, 20420188211034300	1
25	Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. 2021 , 18,	3
24	Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. 2021 , 9, 227-238	4
23	Probiotics, Pre-biotics and Synbiotics in the Treatment of Pre-diabetes: A Systematic Review of Randomized Controlled Trials. 2021 , 9, 645035	1
22	Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring Rats by Modulating Antioxidant Capacity and Gut Microbiota. 2021 , 22,	9
21	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. 2021 , 22,	7
20	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157	2
19	The promise of the gut microbiome as part of individualized treatment strategies. 2021 ,	12
18	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. 2021 , 27, 22-43	14
17	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. 2021 , 27, 110-124	10
16	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. 2017 , 2,	30
15	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. 2020 , 10, 542-555	3
14	Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. 2014 , 20, 569-77	58

13	Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?. 2014 , 20, 9072-89	85
12	Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. 2014 , 20, 16464-73	30
11	Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. 2016 , 22, 91-105	19
10	The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. 2016 , 7, 59	48
9	Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. 2017 , 7, 101-106	19
8	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. 2021 , 12, 761836	5
7	Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis. 2015 , 14, 25-33	8
6	Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.. 2022 , 10,	2
5	Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics.. 2022 , 106, 505	7
4	The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.. 2022 , 10,	7
3	Image_1.JPEG. 2019 ,	
2	Image_2.JPEG. 2019 ,	
1	Image_3.JPEG. 2019 ,	